Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric ( mouse/ human) |
Target | IL-6 |
Clinical data | |
Trade names | Sylvant |
Other names | CNTO 328 |
License data |
|
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6450H9932N1688O2016S50 |
Molar mass | 144983.21 g·mol−1 |
![]() ![]() |
Siltuximab ( INN [4]), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease. [2] [3] It is a chimeric (made from human and mouse proteins) monoclonal antibody that binds to interleukin-6. It is an interleukin-6 (IL-6) antagonist. [2]
The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection. [5]
In April 2014, siltuximab was approved for medical use in the United States for the treatment of people with multicentric Castleman's disease who do not have human immunodeficiency virus ( HIV) or human herpesvirus-8 ( HHV-8). [5] [6]
Siltuximab is indicated for the treatment of people with multicentric Castleman's disease who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. [2] [3]
The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection. [5]
Siltuximab may increase CYP450 activity leading to increased metabolism of drugs that are CYP450 substrates. [2]
Siltuximab is a chimeric monoclonal antibody that binds to interleukin-6 (IL-6), preventing binding to soluble and membrane bound interleukin-6 receptors. Siltuximab interferes with IL-6 mediated growth of B-lymphocytes and plasma cells, secretion of vascular endothelial growth factor ( VEGF) and autoimmune phenomena. [2]
Siltuximab demonstrated efficacy and safety in people with idiopathic multicentric Castleman disease. [7] [8] Treatment results with siltuximab in B-cell non-Hodgkin's lymphoma are inferior to those obtained in multicentric Castleman disease. [9]
The approval by the US FDA was based on an international, multicenter, randomized (2:1), phase II study comparing every three-week intravenous infusions of siltuximab and best supportive care to placebo and best supportive care. [5] The trial enrolled 79 participants and randomly allocated 53 participants to the siltuximab arm plus best supportive care and 26 participants randomized to the placebo arm plus best supportive care. [5] Siltuximab was administered every three weeks as an intravenous infusion at a dose of 11 mg/kg. [5]
Siltuximab has been investigated for the treatment of neoplastic diseases: [10] metastatic renal cell cancer, [11] prostate cancer, [12] other types of cancer, [13] and for Castleman's disease. [14] [15]
Siltuximab has been evaluated in the treatment of ovarian cancer, however the efficacy for this cancer is debatable. [16] In addition, siltuximab has been evaluated for multiple myeloma, but there was an insignificant increase in response rates. [17]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric ( mouse/ human) |
Target | IL-6 |
Clinical data | |
Trade names | Sylvant |
Other names | CNTO 328 |
License data |
|
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6450H9932N1688O2016S50 |
Molar mass | 144983.21 g·mol−1 |
![]() ![]() |
Siltuximab ( INN [4]), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease. [2] [3] It is a chimeric (made from human and mouse proteins) monoclonal antibody that binds to interleukin-6. It is an interleukin-6 (IL-6) antagonist. [2]
The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection. [5]
In April 2014, siltuximab was approved for medical use in the United States for the treatment of people with multicentric Castleman's disease who do not have human immunodeficiency virus ( HIV) or human herpesvirus-8 ( HHV-8). [5] [6]
Siltuximab is indicated for the treatment of people with multicentric Castleman's disease who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. [2] [3]
The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection. [5]
Siltuximab may increase CYP450 activity leading to increased metabolism of drugs that are CYP450 substrates. [2]
Siltuximab is a chimeric monoclonal antibody that binds to interleukin-6 (IL-6), preventing binding to soluble and membrane bound interleukin-6 receptors. Siltuximab interferes with IL-6 mediated growth of B-lymphocytes and plasma cells, secretion of vascular endothelial growth factor ( VEGF) and autoimmune phenomena. [2]
Siltuximab demonstrated efficacy and safety in people with idiopathic multicentric Castleman disease. [7] [8] Treatment results with siltuximab in B-cell non-Hodgkin's lymphoma are inferior to those obtained in multicentric Castleman disease. [9]
The approval by the US FDA was based on an international, multicenter, randomized (2:1), phase II study comparing every three-week intravenous infusions of siltuximab and best supportive care to placebo and best supportive care. [5] The trial enrolled 79 participants and randomly allocated 53 participants to the siltuximab arm plus best supportive care and 26 participants randomized to the placebo arm plus best supportive care. [5] Siltuximab was administered every three weeks as an intravenous infusion at a dose of 11 mg/kg. [5]
Siltuximab has been investigated for the treatment of neoplastic diseases: [10] metastatic renal cell cancer, [11] prostate cancer, [12] other types of cancer, [13] and for Castleman's disease. [14] [15]
Siltuximab has been evaluated in the treatment of ovarian cancer, however the efficacy for this cancer is debatable. [16] In addition, siltuximab has been evaluated for multiple myeloma, but there was an insignificant increase in response rates. [17]